Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Migalastat vs ERT in Fabry Disease (ATTRACT)
NCT01218659Phase 3Completed
- Sponsor
- Amicus Therapeutics
- Start
- Sep 2011
- Primary completion
- May 2014
- Modality
- Classical Binding Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of migalastat in Fabry disease (FD) (2 arms), sponsored by Amicus Therapeutics. Primary endpoints: Annualized Rate of Change in Measured Glomerular Filtration Rate at 18 months and Annualized Rate of Change in Estimated Glomerular Filtration Rate at 18 months. Started Sep 2011; status: completed.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT01218659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218659.